REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
05/18/2026
Back to search
Official data from USPTO
X PARSOLEX PARTNER SOLUTIONS EXCELLENCE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
39
Latest update
05/19/2026
Trademark type
Combined
Nice classes
42
Filing date
08/07/2019
Registration date
05/18/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/18/2021
Last transaction
05/19/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
10/28/2019
First use in commerce
10/28/2019
Drawing code
3
Owner type
03
Owner location
West Lafayette, IN, US
Examiner
BULLOFF, TOBY ELLEN
Law office
N10
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a stylized design comprised of two diagonal intersecting pill capsules forming a heart shaped arrow design on the left side and creating an "x" shape; the design element appears to the left of the wording "Parsolex"; centered underneath the design and "Parsolex" wording appears the wording "PARTNER SOLUTIONS EXCELLENCE".
Holders and representatives
Holders
Parsolex GMP Center, Inc.
Representatives
Jill J. Chalmers BRYAN CAVE LEIGHTON PAISNER LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Consulting services in the fields of pharmaceuticalmedical and healthcare research and development; technical servicesresearch and development in the pharmaceutical and biotechnology fields; consulting services for pharmaceutical formulation designdesign of processes to transform inorganic and organic substances and pharmaceutical technology transfer being advice and information about pharmaceutical research and design; technical servicesproviding adviceinformation and instructions for pharmaceutical formulation design and design of processes to transform inorganic and organic substancespharmaceutical technology transfer being advice and information about pharmaceutical research and design; pharmaceutical product chemical and physical evaluation servicestest method developmenttest method validationuse of test methods for in-process controlquality controlproduct releasetechnology transfer being advice and information about pharmaceutical test methods; analytical chemistry servicesdeveloping and validating test methods for drug product release; technology transfer being advice and information about the drug product testing process and test methods; providing services to others in the fields of analyticalchemistry and manufacturing controls for the production and regulatory approval of pharmaceuticalsproviding scientific information relating to the analysis and management of the pharmaceutical manufacturing process for the productionpackagingregulatory approval of pharmaceuticals; consulting services in the fields of chemistrybiotechnologypharmaceutical research and developmentlaboratory testingdiagnostics; consulting and research and development services in the fields of analytical chemistrybiochemistrymedicinal chemistrydrug developmentbiotechnologymicrobiology and molecular biology; technical consulting in the fields of pharmaceutical studiesresearch and development; technical consulting in the field of pharmaceutical development and engineering; technical consulting in the field of analytical chemistry services; consultancy pertaining to pharmacology; technology consultation in the fields of research and development of pharmaceuticalsmedicines and healthcare products; scientific research consulting in the fields of pharmaceuticalsmedicines and healthcare products; product development consulting in the fields of pharmaceuticalsmedicines and healthcare products; scientific research services relating to pharmaceuticalsmedicines and healthcare products; product development consultation; product development services; formulation and process design services for drug products for others; outsource service provider for manufacturing and packaging of pharmaceuticals; formulation and process design services for drug products for others; design of packaging for pharmaceuticals of others; pharmaceutical product packaging design services for others; formulation and process design services for drug products of others; provision of informationadvice and consultancy in relation to pharmaceutical packaging design; technical consulting in the field of pharmaceutical research and development; custom pharmaceutical service providerpharmaceutical formulation designdesign of processes to transform inorganic and organic substanceschemical and physical evaluation of pharmaceuticals; consulting in the areas of pharmaceutical formulation designdesign of processes to transform inorganic and organic substanceschemical and physical evaluation of pharmaceuticals; development of custom pharmaceuticals for others; design of packaging for pharmaceuticals for others; formulation and process design services for drug products for others
Publications
History of USPTO decisions and trademark events.
39 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
05/18/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
04/16/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
04/15/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/02/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/01/2021
IUAF
USE AMENDMENT FILED
03/17/2021
EISU
TEAS STATEMENT OF USE RECEIVED
03/17/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
09/22/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/28/2020
PUBO
PUBLISHED FOR OPPOSITION
07/28/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/08/2020
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
06/24/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/16/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
06/16/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/16/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
06/16/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/16/2020
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
06/16/2020
ISMR
WITHDRAWN FROM ISSUE - MANAGING ATTORNEY REQUEST
06/15/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/26/2020
PUBO
PUBLISHED FOR OPPOSITION
05/26/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/06/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/22/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
04/22/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/22/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
04/22/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/22/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/16/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/16/2020
ALIE
ASSIGNED TO LIE
04/15/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/08/2020
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
10/31/2019
GPRA
PRIORITY ACTION E-MAILED
10/31/2019
CPRA
PRIORITY ACTION WRITTEN
10/31/2019
DOCK
ASSIGNED TO EXAMINER
10/16/2019
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
08/27/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/24/2019
NWAP
NEW APPLICATION ENTERED
08/10/2019
Continuous trademark protection
Get notified about every new filing that threatens X PARSOLEX PARTNER SOLUTIONS EXCELLENCE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.